Andere talen Ryvu Therapeutics S.A.

Aandelen

RVU

PLSELVT00013

Vertraagde tijd Warsaw S.E. Andere beurzen 14:27:46 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
49,8 ^PLN	-1,97%		-6,92%	-13,39%

13/03	Ryvu Therapeutics S.A. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
06/03	Ryvu Therapeutics presenteert preklinische gegevens over RVU120 en synthetische letaliteitsprogramma's op de jaarlijkse AACR-bijeenkomst in 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	06/03
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	14/02
Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml	31/01
Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023	07/12
Ryvu Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
Ryvu Therapeutics - Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes	23-10-23
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120	23-10-23
Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	17-10-23
Ryvu Therapeutics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13-09-23
Ryvu and TIM to enter Warsaw's mWIG40 index	31-08-23
Ryvu Therapeutics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	16-05-23
Ryvu Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	24-03-23
Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 at the 2022 American Society of Hematology Annual Meeting	11-12-22
MIDDAY BRIEFING - Unternehmen und Märkte	30-11-22
BioNTech Forms Multi-Target Research Collaboration With Ryvu Therapeutics	30-11-22
BioNTech to Make $21 Million Equity Investment in Ryvu Therapeutics	30-11-22
BioNTech SE and Ryvu Therapeutics S.A. Enters into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates	30-11-22
Ryvu Therapeutics S.A. announced that it expects to receive ?20 million in funding from BioNTech SE	30-11-22
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update	24-11-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ryvu Therapeutics S.A.

Aandelen

RVU

PLSELVT00013

Andere talen

Filters